Market News & Trends
Salipro Biotech Strengthens Global IP Portfolio With Two New Patents
Salipro Biotech AB recently announced the issuance of two new patents by the Japanese Patent Office. These patents further solidify the company’s intellectual property (IP)…
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss With RES-010 in Non-Human Primates
Resalis Therapeutics recently presented new preclinical results on its lead candidate RES-010, a first-in-class antisense oligonucleotide targeting microRNA-22 (miR-22). The data was presented at the European…
GLD Partners LP Launches New Biotech Company to Accelerate Drug Discovery for Muscle-Wasting Diseases
GLD Partners LP recently announced the launch of Altagenics, a new biotechnology company leveraging Heligenics’ proprietary GigaAssay platform to accelerate drug discovery. The collaboration will initially…
RheumaGen & SiVEC Biotechnologies Announce CGT Partnership & In Vivo Program to Cure Common Autoimmune Diseases
RheumaGen, Inc. and SiVEC Biotechnologies, Inc. recently announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune…
Terumo Announces Completion of Acquisition of WuXi Biologics Drug Product Plant in Leverkusen, Germany
Terumo Corporation recently announced the successful completion of its acquisition of a Drug Product Plant and associated Quality Control Laboratory operations from WuXi Biologics in Leverkusen,…
NanoPhoria Bioscience Secures Funding to Advance Breakthrough Heart Failure Therapy & Expand Portfolio for Novel Nano-in-Micro Delivery Platform
NanoPhoria Bioscience recently announced the successful first close of its €83.5 million Series A financing round. The round was led by XGEN Venture, Sofinnova Partners,…
Oculis Accelerates Privosegtor Into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-Class Neuroprotective Therapy
Oculis Holding AG recently announced the advancement of Privosegtor into a registrational program for neuro-ophthalmology indications following a positive meeting with the US FDA. Privosegtor…
Dyadic Applied BioSolutions Announces Milestone Achievements & Recent Company Developments
Dyadic International, Inc. recently announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS…
Invivyd Announces US IND Clearance & Alignment With FDA on Pivotal Clinical Program for a Vaccine-Alternative Antibody to Prevent COVID
Invivyd, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application and provided feedback to advance the company’s REVOLUTION clinical…
uniQure’s Gene Therapy for Huntington’s Disease Holds Blockbuster Potential
uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated statistically significant disease slowing in a Huntington’s disease (HD) pivotal trial. The results…
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd. recently announced encouraging results from a recent pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation. The study was designed…
Ovid Announces Positive Topline Results for the Next-Generation GABA-Aminotransferase Inhibitor
Ovid Therapeutics Inc. recently announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity…
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
AM-Pharma B.V. recently announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention…
Bio-Rad Extends Partnership With Gencurix Through Strategic Agreement for Droplet Digital PCR IVD Oncology Kits in Europe
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, and Gencurix, Inc. (KOSDAQ: 229000), a leading…
Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study for the Treatment of Major Depressive Disorder
Draig Therapeutics recently announces that it will initiate a Phase 2 study of DT-101, a next-generation AMPA receptor positive allosteric modulator (PAM) for Major Depressive…
Sitryx Receives FDA Clearance of IND Application for Atopic Dermatitis Treatment
Sitryx Therapeutics recently announced it has received clearance from the US FDA for its Investigational New Drug (IND) application for SYX-5219, to support the initiation…
Aerska Launches With $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain
Aerska, a biotechnology company aiming to redefine the treatment of neurological diseases, recently announced it has raised $21 million in seed financing, co-led by Age1,…
RheumaGen Announces Oral Presentation on HLA Gene-Editing Preclinical Data for Lead Autoimmune Disease Program at ACR Convergence 2025
RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, today announced that a human leukocyte antigen…
Fortress Biotech & Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary, recently announced Crystalys Therapeutics, Inc., in which Urica maintains an equity position, closed a $205 million Series…
Symbiosis Expands Sterile Manufacturing Capacity With Fill/Finish Line Qualification
Symbiosis Pharmaceutical Services has successfully completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production facility in Stirling, Scotland. The…
